Dr. Moustafa Gabr, an assistant professor of chemistry in Radiology, specializing in small molecule drug discovery, was recently awarded four R01 grants and one RF1 grant each surpassing $1M, focusing on modulating the immune system with small molecules to develop therapies for cancer and neurological disorders. In this area, he has pioneered an innovative hit identification workflow that facilitates the discovery of first-in-class small molecules targeting immune cell receptors. This groundbreaking approach integrates screening technologies with advanced computational modeling, allowing for rapid identification of compounds that selectively bind to specific receptors on immune cells.
Each of the projects is based on a five-year timeline and increases opportunities for collaboration. “I’m particularly excited about emerging interdisciplinary collaborations with leaders in glioblastoma therapies from Stanford, Harvard, and Northwestern, which will enhance our approach to translational drug discovery by integrating diverse expertise and innovative methodologies to tackle complex challenges,” said Dr. Gabr.
Dr. Gabr credits his success in receiving these grants with the same tactics he employed as an early-career scientist, developing a cohesive research agenda that builds collaboration, aligning his proposals with NIH priorities, seeking feedback and mentorship, and dedicating focused time to grant writing. “Securing five R01 grants in translational drug discovery highlights my commitment to advancing therapies that bridge laboratory findings to clinical applications. Each grant targets key challenges in drug development, promotes collaboration across disciplines, and supports the training of early-career scientists.”
“I envision the outcomes of my research driving advancements in translational drug discovery, ultimately leading to more effective therapies for cancer and neurological disorders. This work could also influence future directions by identifying new targets and methodologies that shape ongoing drug discovery research efforts.”